Blocking Growth Hormone in Middle-Aged Mice Extends Lifespan Significantly
Switching off growth hormone receptors at midlife — not birth — meaningfully extended lifespan in mice, pointing toward a viable human aging intervention.
Summary
A new study in Aging Cell shows that knocking out the growth hormone receptor in mice at 12 months of age — roughly equivalent to human midlife — significantly extended lifespan in both sexes. The longest-lived female mice with the knockout outlived their normal counterparts by four months. Despite gaining fat mass and losing lean mass, the mice showed no increase in inflammatory markers, maintained physical performance, and males showed improved insulin sensitivity and lower fasting glucose. Vertebral bone density was preserved in males. These findings build on earlier work showing lifelong or young-adult growth hormone suppression extends life, but critically demonstrate the effect holds even when the intervention begins in midlife — the timeframe most relevant to human therapeutic use.
Detailed Summary
Growth hormone plays a central role in how we age. It raises circulating fatty acids, boosts IGF-1, and impairs insulin function — a metabolic profile closely tied to accelerated aging. Humans born with an inability to respond to growth hormone, a condition called Laron syndrome, are notably resistant to diabetes, cognitive decline, and cardiovascular disease. Mice engineered to have low growth hormone similarly live longer and suffer less age-related disease. The catch has always been that these models alter growth hormone from birth, making them irrelevant to clinical treatment in adults whose growth is already complete.
This study addressed that gap directly. Researchers created a mouse model in which the growth hormone receptor (GHR) is knocked out at 12 months — roughly human midlife — and tracked the animals through the rest of their lives. Both males and females showed improved survival curves. The effect was most pronounced among the longest-lived animals: the longest-surviving female GHR knockout mice outlived the longest-surviving female controls by a full four months.
Surprisingly, the metabolic picture was mixed but largely reassuring. Both sexes gained fat mass and lost lean mass compared to controls — a pattern usually associated with poor health outcomes. Yet inflammatory markers remained stable, physical strength tests were unaffected, and male mice showed meaningfully better insulin responses and lower fasting glucose. Females were unaffected metabolically in those measures.
Bone health improved in males, with vertebral trabecular bone density resembling that of younger animals. Liver gene expression shifted substantially in both sexes, with male livers beginning to express a more female-like gene pattern — an intriguing finding the researchers link to the known sex-specific effects of growth hormone signaling.
The study is preclinical and mouse-based, so direct human translation is not yet established. However, the midlife timing of the intervention is a critical proof of concept: it suggests that targeting the GH/IGF-1 axis in adults — after growth is complete — could meaningfully extend healthy lifespan without disrupting development.
Key Findings
- GHR knockout at midlife extended maximum female lifespan by four months compared to controls.
- Both male and female mice showed improved survival curves despite increased fat mass.
- Male mice had better insulin sensitivity and lower fasting glucose after midlife GHR knockout.
- Vertebral bone mineral density was preserved in males, resembling that of younger mice.
- Physical performance tests showed no weakness despite reduced lean mass, challenging typical fat-gain concerns.
Methodology
This is a research summary based on a peer-reviewed study published in Aging Cell, a reputable aging-biology journal. The evidence comes from a controlled mouse model using conditional GHR knockout at 12 months of age. Both sexes were studied with appropriate control groups, and multiple healthspan endpoints — metabolic, physical, skeletal, and transcriptomic — were assessed.
Study Limitations
This is a mouse study and may not translate directly to human biology, particularly given known species differences in GH signaling. The full paper's conclusion section was truncated in the source article, so some interpretations and caveats from the authors may be missing. The mechanism behind the fat-mass increase without metabolic harm warrants further investigation before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: